Brigimadlin: MDM2-p53 antagonist
Phase 1
Therapeutic Area: Oncology
Anchored in external partnership or acquisition
Through our ongoing research and in partnership with experts in this field, we intend to expand our knowledge about the role of the MDM2-p53 pathway in cancer development. This pathway is an area of high interest for the scientific community as approximately 5-7% of tumors display MDM2 amplifications.
Our investigational MDM2-p53 antagonist is a highly potent, oral, small molecule compound that inhibits the interaction between MDM2 and p53, restoring p53 wild type function.